Bepotastine

Bepotastine

SCHEMBL29459

O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

HRH1

The experimentally established mechanism targets of Bepotastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 known ✓ P35367 1/20 0.48
BCHE P06276 6/20 0.55
DRD2 P14416 10/20 0.51
NPC1 O15118 1/20 0.48
MLNR O43193 1/20 0.48
NR1I2 O75469 1/20 0.48
EGFR P00533 1/20 0.48
LMNA P02545 1/20 0.48
ERBB2 P04626 1/20 0.48
FYN P06241 1/20 0.48
CHRM2 P08172 1/20 0.48
CHRM4 P08173 1/20 0.48
ABCB1 P08183 1/20 0.48
ADRB1 P08588 1/20 0.48
HTR1A P08908 1/20 0.48
CHRM5 P08912 1/20 0.48
ADRA2A P08913 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
CHRM1 P11229 1/20 0.48
ADRB3 P13945 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bepotastine SCHEMBL5151702 1.00 BCHE (0.55) BCHEDRD2NPC1MLNRNR1I2
Bepotastine SCHEMBL726880 1.00 BCHE (0.55) BCHEDRD2NPC1MLNRNR1I2
Bepotastine SCHEMBL30200949 1.00 BCHE (0.55) BCHEDRD2NPC1MLNRNR1I2
Bepotastine SCHEMBL29440897 1.00 BCHE (0.55) BCHEDRD2NPC1MLNRNR1I2
Bepotastine SCHEMBL2808049 0.99 BCHE (0.55) BCHEDRD2NPC1MLNRNR1I2
Bepotastine SCHEMBL2803678 0.99 BCHE (0.55) BCHEDRD2NPC1MLNRNR1I2
Bepotastine SCHEMBL2806225 0.99 BCHE (0.55) BCHEDRD2NPC1MLNRNR1I2
Bepotastine SCHEMBL2807641 0.99 BCHE (0.55) BCHEDRD2NPC1MLNRNR1I2
SCHEMBL28391952 0.96 BCHE (0.56) BCHEDRD2NPC1MLNRNR1I2
Bepotastine SCHEMBL2804852 0.95 BCHE (0.54) BCHEDRD2NPC1MLNRNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3428 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260139860-A1 PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS CENTRE FOR DIGESTIVE DISEASES (AU) 2026-05-21 US claimed
WO-2026100654-A1 NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD 株式会社インファーマシア 2026-05-15 WO claimed
US-20260076872-A1 POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME SIO2 MEDICAL PRODUCTS LLC (US) 2026-03-19 US claimed
EP-4680248-A1 PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM Topelia Aust Limited (ACN 652 771 670) (AU) 2026-01-21 EP claimed
EP-4673157-A2 COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME Persephone Biosciences, Inc. (US) 2026-01-07 EP claimed
WO-2025264805-A2 SYNBIOTICS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME PERSEPHONE BIOSCIENCES, INC. (US) 2025-12-26 WO claimed
US-20250275951-A1 DRUGS TARGETING INFLAMMATION FOR THE TREATMENT OF OSTEOARTHRITIS AND OTHER INFLAMMATORY DISEASES THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2025-09-04 US claimed
US-20250269005-A1 METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT TOPELIA AUST LIMITED (ACN 652 771 670) (AU) 2025-08-28 US claimed
US-20250242092-A1 SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS SIO2 MEDICAL PRODUCTS INC (US) 2025-07-31 US claimed
EP-4580677-A2 SARS-COV2 ANTIBODIES AND USES THEREOF Invivyd, Inc. (US) 2025-07-09 EP claimed
US-20050107429-A1 water solutions comprising (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid monobenzenesulfonate, stabilized with water-soluble metal chlorides; eye or nose drops SENJU PHARMACEUTICAL CO., LTD. (JP) 2005-05-19 US claimed
EP-1525884-A1 AQUEOUS LIQUID PREPARATIONS AND LIGHT-STABILIZED AQUEOUS LIQUID PREPARATIONS Senju Pharmaceutical Co., Ltd. (JP) 2005-04-27 EP claimed
EP-1482938-A1 PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST ALTANA Pharma AG (DE) 2004-12-08 EP claimed
US-6780877-B2 ANTIHISTAMINIC ACTIVITY, ANTI-ALLERGIC ACTIVITY UBE INDUSTRIES, LTD. (JP) 2004-08-24 US claimed
WO-2004019955-A1 THE USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS ALTANA PHARMA AG (DE) 2004-03-11 WO claimed
WO-2003074055-A1 PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST ALTANA PHARMA AG (DE) 2003-09-12 WO claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
EP-0949260-B1 ACID-ADDITION SALTS OF OPTICALLY ACTIVE PIPERIDINE COMPOUND AND PROCESS FOR PRODUCING THE SAME UBE INDUSTRIES (JP) 2002-05-22 EP claimed
US-20020026054-A1 Acid addition salt of optically active piperidine compound and process for preparing the same UBE INDUSTRIES, LTD. 2002-02-28 US claimed
EP-0949260-A1 ACID-ADDITION SALTS OF OPTICALLY ACTIVE PIPERIDINE COMPOUND AND PROCESS FOR PRODUCING THE SAME UBE INDUSTRIES, LTD. (JP) 1999-10-13 EP claimed